Have a feature idea you'd love to see implemented?
Let us know!
NKTR Nektar Therapeutics
Price (delayed)
$1.3
Market cap
$239.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.9
Enterprise value
$323.46M
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines.
Highlights
Nektar Therapeutics's EPS has increased by 45% YoY and by 2.2% QoQ
The net income has grown by 42% year-on-year
Nektar Therapeutics's equity has shrunk by 60% YoY and by 37% QoQ
Nektar Therapeutics's quick ratio has decreased by 41% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of NKTR
Market
Valuations
Earnings
Shares outstanding
184.08M
Market cap
$239.3M
Enterprise value
$323.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
3
Price to sales (P/S)
2.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.47
Revenue
$93.16M
EBIT
-$152.44M
EBITDA
-$146.03M
Free cash flow
-$174.13M
Per share
Balance sheet
Liquidity
EPS
-$0.9
Free cash flow per share
-$0.83
Book value per share
$0.43
Revenue per share
$0.45
TBVPS
$1.64
Total assets
$343.33M
Total liabilities
$263.65M
Debt
$112.1M
Equity
$79.69M
Working capital
$237.86M
Debt to equity
1.41
Current ratio
5.15
Quick ratio
4.75
Net debt/EBITDA
-0.58
Margins
Efficiency
Dividend
EBITDA margin
-156.8%
Gross margin
59.2%
Net margin
-190.1%
Operating margin
-175.6%
Return on assets
-44.8%
Return on equity
-142.6%
Return on invested capital
-36.8%
Return on capital employed
-53.3%
Return on sales
-163.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NKTR stock price
How has the Nektar Therapeutics stock price performed over time
Intraday
-1.52%
1 week
0%
1 month
-0.76%
1 year
141.64%
YTD
130.09%
QTD
0%
Financial performance
How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$93.16M
Gross profit
$55.17M
Operating income
-$163.58M
Net income
-$177.08M
Gross margin
59.2%
Net margin
-190.1%
The operating margin has grown by 47% YoY and by 3.7% from the previous quarter
The net margin has increased by 46% YoY and by 2.5% QoQ
The operating income is up by 44% year-on-year
The net income has grown by 42% year-on-year
Growth
What is Nektar Therapeutics's growth rate over time
Valuation
What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
3
P/S
2.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.47
Nektar Therapeutics's EPS has increased by 45% YoY and by 2.2% QoQ
The P/B is 117% above the last 4 quarters average of 1.4 and 38% above the 5-year quarterly average of 2.2
Nektar Therapeutics's equity has shrunk by 60% YoY and by 37% QoQ
The stock's P/S is 79% less than its 5-year quarterly average of 14.4 but 64% more than its last 4 quarters average of 1.8
The revenue has grown by 6% YoY and by 3.3% from the previous quarter
Efficiency
How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's return on sales has increased by 48% YoY and by 2.7% QoQ
Nektar Therapeutics's ROE has decreased by 41% YoY and by 24% from the previous quarter
The return on invested capital has grown by 23% year-on-year but it has declined by 10% since the previous quarter
NKTR's ROA is down by 10% from the previous quarter but it is up by 7% YoY
Dividends
What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NKTR.
Financial health
How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 30% more than its total liabilities
The company's current ratio fell by 41% YoY and by 16% QoQ
Nektar Therapeutics's quick ratio has decreased by 41% YoY and by 15% from the previous quarter
The debt is 41% higher than the equity
The debt to equity has soared by 124% YoY and by 57% QoQ
Nektar Therapeutics's equity has shrunk by 60% YoY and by 37% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.